John L. Vahle

2.4k total citations
37 papers, 1.6k citations indexed

About

John L. Vahle is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, John L. Vahle has authored 37 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 12 papers in Immunology and 9 papers in Oncology. Recurrent topics in John L. Vahle's work include Immunotoxicology and immune responses (7 papers), Animal testing and alternatives (7 papers) and Bone health and treatments (6 papers). John L. Vahle is often cited by papers focused on Immunotoxicology and immune responses (7 papers), Animal testing and alternatives (7 papers) and Bone health and treatments (6 papers). John L. Vahle collaborates with scholars based in United States, Germany and United Kingdom. John L. Vahle's co-authors include Michael S. Westmore, Masahiko Sato, Gerald G. Long, Young Linda, Jamie Young, James B. Nold, Jeffery A. Engelhardt, Paul C. Francis, George E. Sandusky and Joseph S. Haynes and has published in prestigious journals such as SHILAP Revista de lepidopterología, Endocrinology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

John L. Vahle

35 papers receiving 1.5k citations

Peers

Countries citing papers authored by John L. Vahle

Since Specialization

Citations

This map shows the geographic impact of John L. Vahle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Vahle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Vahle more than expected).

Fields of papers citing papers by John L. Vahle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John L. Vahle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Vahle. The network helps show where John L. Vahle may publish in the future.

Co-authorship network of co-authors of John L. Vahle

This figure shows the co-authorship network connecting the top 25 collaborators of John L. Vahle. A scholar is included among the top collaborators of John L. Vahle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Vahle. John L. Vahle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies 2024 ·Toxicologic Pathology ·Kevin S. McDorman, Bindu Bennet, Karyn Colman, James Fikes, Natalie Keirstead, Lynda Lanning, (unknown), (unknown), Kenneth A. Schafer, Frédéric Schorsch, Michael S. Thibodeau, Heath C. Thomas, Sean P. Troth, John L. Vahle, Frank J. Geoly	0
2	ICH S1 prospective evaluation study and weight of evidence assessments: commentary from industry representatives 2024 ·SHILAP Revista de lepidopterología ·John L. Vahle, (unknown), Michael J. Graziano, Shigeru Hisada, José Antonio Lebrón, Thomas Nolte, Ronald W. Steigerwalt, (unknown), Frank D. Sistare	4
3	Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals 2024 ·Regulatory Toxicology and Pharmacology ·Andrew W. Harrell, (unknown), John L. Vahle, (unknown), Mario Beilmann, Graeme Young, Kylie A. Beattie, (unknown), (unknown), (unknown)	8
4	Inspiration and Exasperation: The Challenges of Inhaled Biologics 2021 ·Toxicologic Pathology ·(unknown), John L. Vahle, Karyn Colman	2
5	Use of toxicogenomics in drug safety evaluation: Current status and an industry perspective 2018 ·Regulatory Toxicology and Pharmacology ·John L. Vahle, (unknown), Eric A.G. Blomme, Jean-Christophe Hoflack, Daniel P. Stiehl	16
6	Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union 2017 ·Regulatory Toxicology and Pharmacology ·Richard A. Byrd, Rebecca A. Owens, Jamie L. Blackbourne, David E. Coutant, Mark W. Farmen, M. Dodson Michael, Julie S. Moyers, A. Eric Schultze, Michael K. Sievert, Niraj Tripathi, John L. Vahle	4
7	Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action 2017 ·Toxicologic Pathology ·Richard A. Byrd, Jamie L. Blackbourne, Mary Pat Knadler, A. Eric Schultze, John L. Vahle	6
8	Nonproliferative and Proliferative Lesions of the Rat and Mouse Skeletal Tissues (Bones, Joints, and Teeth) 2016 ·Journal of Toxicologic Pathology ·Stacey Fossey, John L. Vahle, Philip H. Long, Scott H. Schelling, Heinrich Ernst, Rogely Boyce, Jacquelin Jolette, Brad Bolon, Alison M. Bendele, Matthias Rinke, Laura Healy, (unknown), Daniel Roth, Michael Boyle, Joel R. Leininger	19
9	Rat-Specific Decreases in Platelet Count Caused by a Humanized Monoclonal Antibody Against Sclerostin 2011 ·Toxicological Sciences ·Daniel G. Rudmann, Todd J. Page, John L. Vahle, Luc Chouinard, Solomon Hailé, (unknown), Gary B. Baskin, (unknown), Pamela G. Walker, (unknown), (unknown), Lise Bernier	10
10	Best Practices for Clinical Pathology Testing in Carcinogenicity Studies 2011 ·Toxicologic Pathology ·Jamie Young, Robert L. Hall, Peter J. O’Brien, Volker Strauss, John L. Vahle	8
11	Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals 2010 ·Toxicologic Pathology ·John L. Vahle, Gregory L. Finch, Shawn M. Heidel, David N. Hovland, Inge A. Ivens, (unknown), Rafael Ponce, Clifford Sachs, Ronald W. Steigerwalt, Brian Short, Marque D. Todd	16
12	Proceedings of the 2009 National Toxicology Program Satellite Symposium 2009 ·Toxicologic Pathology ·Ute Bach, James R. Hailey, (unknown), Wolfgang Kaufmann, Kenneth S. Latimer, David E. Malarkey, R Maronpot, Rodney A. Miller, (unknown), James P. Morrison, Thomas Nolte, Matthias Rinke, Susanne Rittinghausen, Andrew W. Suttie, Gregory S. Travlos, John L. Vahle, Gabrielle A. Willson, Susan A. Elmore	14
13	Lack of Bone Neoplasms and Persistence of Bone Efficacy in Cynomolgus Macaques After Long-Term Treatment With Teriparatide [rhPTH(1-34)] 2008 ·Journal of Bone and Mineral Research ·John L. Vahle, (unknown), Allen Schmidt, Michael S. Westmore, Peiqi Chen, Masahiko Sato	40
14	Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: Is 6 months still appropriate? 2007 ·Regulatory Toxicology and Pharmacology ·Janet Clarke, Christopher Hurst, Pauline L. Martin, John L. Vahle, Rafael Ponce, Barbara Mounho, Shawn M. Heidel, Laura Andrews, Theresa Reynolds, Joy Cavagnaro	33
15	Teriparatide [PTH(1–34)] Strengthens the Proximal Femur of Ovariectomized Nonhuman Primates Despite Increasing Porosity 2004 ·Journal of Bone and Mineral Research ·Masahiko Sato, Michael S. Westmore, Yanfei Li, Allen Schmidt, Qing Zeng, Emmett V. Glass, John L. Vahle, Robert Brommage, Christopher P. Jerome, Charles H. Turner	121
16	Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety 2002 ·Toxicologic Pathology ·John L. Vahle, Masahiko Sato, Gerald G. Long, Jamie Young, Paul C. Francis, Jeffery A. Engelhardt, Michael S. Westmore, Young Linda, James B. Nold	497
17	Skeletal Efficacy with Parathyroid Hormone in Rats Was Not Entirely Beneficial with Long-Term Treatment 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Masahiko Sato, (unknown), Janet M. Hock, Michael S. Westmore, John L. Vahle, (unknown), Charles H. Turner	30
18	Abnormal Bone Architecture and Biomechanical Properties with Near-Lifetime Treatment of Rats with PTH 2002 ·Endocrinology ·Masahiko Sato, John L. Vahle, Allen Schmidt, Michael S. Westmore, Steven R. Smith, Ellen R. Rowley, (unknown)	56
19	Production and characterization of canine osteosarcoma cell lines that induce transplantable tumors in nude mice 1998 ·American Journal of Veterinary Research ·Mary Ann Nieves, John L. Vahle, Mark R. Ackermann, (unknown), Allan B. Dietz, Susan Carpenter, N. F. Cheville	7
20	Pathogenesis of Haemophilus parasuis Infection: Update of Current Research 1995 ·Iowa State University Digital Repository (Iowa State University) ·John L. Vahle, Joseph S. Haynes, John J. Andrews	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact